Assessment of K‐ras mutation

A genetic model for colorectal tumorigenesis

1990 • 11,800 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Cancer Statistics, 2008

2008 • 10,165 citations

Genetic Alterations during Colorectal-Tumor Development

1988 • 6,691 citations

AJCC Cancer Staging Manual

2002 • 6,356 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 • 3,476 citations

Targeting RAS signalling pathways in cancer therapy

2003 • 3,105 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

AJCC Cancer Staging Manual. 6th ed

2002 • 2,374 citations

Proteins regulating Ras and its relatives

1993 • 1,930 citations

Phosphatidylinositol-3-OH kinase direct target of Ras

1994 • 1,923 citations

Prevalence of ras gene mutations in human colorectal cancers

1987 • 1,866 citations

Ras oncogenes: split personalities

2008 • 1,405 citations

Allelotype of Colorectal Carcinomas

1989 • 1,333 citations

Detection of high incidence of K-ras oncogenes during human colon tumorigenesis

1987 • 1,074 citations

Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

2004 • 1,058 citations

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway

1997 • 1,050 citations

ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK

1992 • 948 citations

Systemic Therapy for Colorectal Cancer

2019 • 872 citations

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

2001 • 858 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study

1998 • 739 citations

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

1997 • 699 citations

Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

2005 • 673 citations

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

1999 • 538 citations

Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer

2002 • 495 citations

Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.

1992 • 490 citations

Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.

2001 • 422 citations

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancer

1993 • 415 citations

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

2008 • 377 citations

Clinical significance of ras oncogene activation in human lung cancer

1993 • 361 citations

Allelic Loss in Colorectal Carcinoma

1989 • 338 citations

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

2005 • 324 citations

Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.

2000 • 313 citations

Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers

2008 • 310 citations

Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.

1994 • 281 citations

Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]

1989 • 273 citations

Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.

1994 • 270 citations

The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma

2005 • 248 citations

EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma

1998 • 243 citations

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

2008 • 242 citations

Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas

2000 • 236 citations

K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer

2001 • 236 citations

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

2002 • 224 citations

Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type

1993 • 208 citations

Oncogenic K-RAS Is Required to Maintain Changes in Cytoskeletal Organization, Adhesion, and Motility in Colon Cancer Cells

2005 • 126 citations

New Tumor-Node-Metastasis Staging Strategy for Node-Positive (stage III) Rectal Cancer: An Analysis

2004 • 95 citations

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

2008 • 93 citations

EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer

2007 • 80 citations

K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients

1997 • 71 citations

Prognostic value of K- ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer

2001 • 68 citations

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness

1995 • 67 citations

Oncogenic K‐ras promotes early carcinogenesis in the mouse proximal colon

2008 • 63 citations

Control of colorectal metastasis formation by K-Ras

2005 • 60 citations

Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis

1999 • 53 citations

Expression of matrix metalloproteinase matrilysin (mmp‐7) was induced by activated ki‐ras via ap‐1 activation in sw1417 colon cancer cells

1995 • 50 citations

Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator.

1991 • 46 citations

APC and K-ras gene mutation in aberrant crypt foci of human colon

2001 • 44 citations

K-ras mutations in patients with early colorectal cancers

1997 • 40 citations

The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

2007 • 35 citations

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors

2008 • 30 citations

Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment

2008 • 27 citations

Chromosomal instability andAPC gene mutations in human sporadic colorectal adenomas

2004 • 27 citations

Near‐diploid and near‐triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status

2003 • 20 citations

KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab

2007 • 20 citations